Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Adaptimmune Therapeutics ( (ADAP) ) has shared an announcement.
On August 7, 2025, Adaptimmune announced the termination of Dr. Elliot Norry as Chief Medical Officer, effective August 8, 2025, due to redundancy. Dr. Norry will receive a severance package including a year’s salary and healthcare coverage. Similarly, Dr. Joanna Brewer’s role as Chief Scientific Officer will end on August 31, 2025, with a similar severance arrangement. Gavin Wood’s termination as Chief Financial Officer, initially announced in December 2024, will also conclude on August 31, 2025, with a severance package including a year’s salary and a pro rata bonus. These changes reflect a strategic restructuring within the company.
The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
Spark’s Take on ADAP Stock
According to Spark, TipRanks’ AI Analyst, ADAP is a Neutral.
Adaptimmune Therapeutics faces significant financial challenges with persistent losses and negative equity, heavily impacting the overall score. While recent corporate events and operational achievements provide some positive outlook, the technical indicators and valuation remain weak, reflecting ongoing risks.
To see Spark’s full report on ADAP stock, click here.
More about Adaptimmune Therapeutics
Adaptimmune Therapeutics is a biotechnology company focused on developing T-cell therapies for cancer treatment.
Average Trading Volume: 15,508,073
Technical Sentiment Signal: Sell
Current Market Cap: $24.52M
See more insights into ADAP stock on TipRanks’ Stock Analysis page.